Dasatinib vs Natural Senolytics: When to Choose the Pharmaceutical Option

Expert Summary

Dasatinib + quercetin has stronger human evidence for senolytic activity than any natural alternative. Fisetin and quercetin alone have stronger evidence than many early-stage pharmaceuticals. The choice depends on: age, disease burden, access, risk tolerance, and cost. Most practitioners recommend starting with natural senolytics in one's 40s–50s and considering D+Q consultation from one's 60s onwards.

Key Facts

Frequently Asked Questions

Can natural senolytics completely replace D+Q?

They cannot replicate D+Q's specific kinase inhibition mechanism or its evidence base. However, for individuals unwilling or unable to access dasatinib, fisetin + quercetin represent a meaningful and evidence-supported alternative.

At what age should I switch to D+Q?

There is no strict age threshold. Consider D+Q when: natural senolytic protocols show diminishing symptom improvement, age-related functional decline is accelerating, or when a longevity physician recommends it based on biomarkers and health history.

Can I take D+Q and natural senolytics on the same cycle?

The D+Q protocol already includes quercetin. Adding fisetin on the same burst days potentially amplifies senolytic coverage. There are no documented pharmacokinetic interactions between fisetin and dasatinib.

Get the free Longevity Supplement Starter Guide

Sign up for the guide and occasional Stacking Years updates. The guide is available on the confirmation screen.

Scientific References